Metabolic & Weight
Pancragen
Khavinson pancreas bioregulator
Khavinson short peptide bioregulator
This Pancragen entry draws on 3 cited sources published 2020 to 2021. The evidence available is graded Russian Research on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Khavinson short peptide bioregulator
- Drug class
- Metabolic & Weight
- Structure
- Tetrapeptide (Khavinson class)
- Route
- Oral
- Half-life
- Short (minutes)
- Evidence tier
- Russian Research
- Availability
- Research
- Research depth
- 22 indexed citations →
Mechanism of action
Tissue-specific gene expression in pancreatic beta-cells
Reported areas of research
Pancreatic beta-cell support; glucose metabolism (animal/early human)
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Oral capsule 1-2x daily
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Sparse controlled trials
Compared with
Pancragen has published head-to-head comparisons with 16 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
- Pancragen vs Bronchogen
- Pancragen vs Cardiogen
- Pancragen vs Cartalax
- Pancragen vs Chonluten
- Pancragen vs Cortagen
- Pancragen vs Crystagen
- Pancragen vs Epitalon
- Pancragen vs Livagen
- Pancragen vs Ovagen
- Pancragen vs Pinealon
- Pancragen vs Prostamax
- Pancragen vs Testagen
- Pancragen vs Thymagen
- Pancragen vs Vesilute
- Pancragen vs Vesugen
- Pancragen vs Vilon
Frequently asked questions
What dosing is reported for Pancragen in research literature?
Published peptide research reports the following dosing approach for Pancragen: Oral capsule 1-2x daily. This is a research reference, not a clinical recommendation.
How is Pancragen administered in research?
Pancragen is administered via the following routes in published studies: Oral.
What is the reported half-life of Pancragen?
No measured half-life for Pancragen is reported in the literature catalogued here. The catalog describes it as: Short (minutes).
Is Pancragen FDA-approved?
No. Pancragen is not an FDA-approved drug. PeptideHelper.org catalog status: Research.
What level of evidence supports Pancragen?
The current evidence base for Pancragen is best characterised as: Russian Research. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Pancragen?
Known concerns reported in the literature for Pancragen include: Sparse controlled trials. Always consult a qualified clinician before any human use.
Is there anyone who should not use Pancragen?
No formal contraindications are established for Pancragen, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Sparse controlled trials. Always consult a qualified clinician before any human use.
How does Pancragen work?
The mechanism of action reported for Pancragen in the literature: Tissue-specific gene expression in pancreatic beta-cells.
What is Pancragen studied for?
Pancragen has been studied in the published literature for: Pancreatic beta-cell support; glucose metabolism (animal/early human). These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Pancragen?
Pancragen is classified as: Khavinson short peptide bioregulator. Also known as: Khavinson pancreas bioregulator.
Drug class
- Khavinson peptides, see all peptides tagged Khavinson.
Research focus area
All peptides studied for Metabolic & Weight, ranked by evidence tier and regulatory status.
Primary sources
- Khavinson VK et al. Peptide regulation of gene expression — a systematic review. Molecules 2021. PMID 34834147
- Khavinson V et al. Peptide regulation of cell differentiation. Stem Cell Rev Rep 2020. PMID 31808038
- Note: Primary literature on this peptide is published largely in Russian gerontology journals (Adv Gerontol, Bull Eksp Biol Med). English-indexed sources are limited to comprehensive Khavinson-laboratory reviews; entry confidence is correspondingly lower.
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…